Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.580
-0.130-2.28%
Volume:35.27M
Turnover:195.82M
Market Cap:104.25B
PE:36.73
High:5.630
Open:5.605
Low:5.440
Close:5.710
52wk High:8.335
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.58
T/O Rate:0.19%
Dividend:0.12
Dividend Rate:2.15%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.74
PE(LYR):36.73
PS:2.64

Loading ...

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers

Stock News
·
Sep 21

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 21

Hang Seng Index Rallies into the Close, up More Than 1%, Testing the 25,000 Level

Tiger Newspress
·
Sep 21

Hong Kong Stock Movers | SBP Group Surges Over 6% as Management Reaffirms Annual Revenue Target, with Newly Approved Innovative Drugs Set to Drive Sustained Sales Growth

Stock News
·
Sep 21

Movement Alert|SBP GROUP Rises 3.11% in Regular Trading, Management Reaffirms Double-Digit Revenue Growth Guidance with Buy Rating from Daiwa

Market Focus
·
Sep 21

Daiwa Reaffirms Buy Rating on SBP Group After Management Reiterates Double-Digit Revenue Growth Target for the Year

Deep News
·
Sep 20

Daiwa Highlights SBP Group's Reaffirmed Double-Digit Revenue Growth Target for This Year, Retains "Buy" Rating

Stock News
·
Sep 18

Movement Alert|SBP GROUP Rises 3.18% in Regular Trading, Dual NDA Acceptances and CT Tianqing Stake Increase Completion Fuel Gains

Market Focus
·
Sep 18

Hong Kong Stocks in Focus: SBP Group Jumps Nearly 3% on Double New Drug Approval Submissions

Stock News
·
Sep 16

Sino Biopharmaceutical Says China's CDE Accepts NDA for Tqh2722 Injection

Reuters
·
Sep 16

Hong Kong Market Open: Hang Seng Index Rises 0.50% as Optics Stocks Rally, CATL Slides Over 2%

Stock News
·
Sep 16

Chinese Regulator Accepts NDA for Sino Biopharm's Breast Cancer Drug

MT Newswires Live
·
Sep 16

Sino Biopharm (SBP Group) Receives CDE Acceptance of NDA for IL-4Rα Monoclonal Antibody TQH2722 Targeting Moderate-to-Severe Atopic Dermatitis

Bulletin Express
·
Sep 16

China Biopharmaceuticals Advances Novel HER2-Targeting Bispecific ADC Toward Market Approval

Stock News
·
Sep 16

Sino Biopharmaceutical - China Cde Accepts New Drug Application for Tqb2102 Injection

THOMSON REUTERS
·
Sep 16

Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong

Dow Jones
·
Sep 15

Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Sino Biopharmaceutical Climbs on Plan to Raise Stake in Core Unit

Reuters
·
Sep 14